Gene-expression profiling to predict responsiveness to immunotherapy

Jamieson, N.B. and Maker, A.V. (2017) Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Therapy, 24(3), pp. 134-140. (doi: 10.1038/cgt.2016.63) (PMID:27834354)

Full text not currently available from Enlighten.


Recent clinical successes with immunotherapy have resulted in expanding indications for cancer therapy. To enhance antitumor immune responses, and to better choose specific strategies matched to patient and tumor characteristics, genomic-driven precision immunotherapy will be necessary. Herein, we explore the role that tumor gene-expression profiling (GEP) may have in the prediction of an immunotherapeutic response. Genetic markers associated with response to immunotherapy are addressed as they pertain to the tumor genomic landscape, the extent of DNA damage, tumor mutational load and tumor-specific neoantigens. Furthermore, genetic markers associated with resistance to checkpoint blockade and relapse are reviewed. Finally, the utility of GEP to identify new tumor types for immunotherapy and implications for combinatorial strategies are summarized.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Jamieson, Dr Nigel
Authors: Jamieson, N.B., and Maker, A.V.
College/School:College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing > Dental School
Journal Name:Cancer Gene Therapy
Publisher:Nature Publishing Group
ISSN (Online):1476-5500
Published Online:11 November 2016

University Staff: Request a correction | Enlighten Editors: Update this record